The FDA and CDC recommended a pause for Ixchiq, a chikungunya vaccine, following reports of adverse events in recipients 60 ...

NEW YORK (AP) — The U.S. government advised American travelers age 60 and older not get a chikungunya vaccine as it ...

Both the FDA and EMA have suspended Ixchiq’s use in older adults after post-marketing serious adverse events that include two ...

The decision follows ongoing investigations into serious adverse events primarily reported in elderly individuals who ...

FDA and CDC recommend halting Ixchiq vaccine use in adults 60 and older after reports of serious adverse events, including ...

Valneva (VALN) stock is in focus as the U.S. recommends a pause in the company's chikungunya vaccine Ixchiq in adults 60+ ...

The FDA and CDC have also recommended pausing the use of Ixchiq in seniors 60 years and older while safety investigations are ...

The use of Valneva’s chikungunya vaccine, known under the brand name Ixchiq, has been paused in elderly individuals after reports of serious adverse events (AEs) The US Food and Drug ...

The European Union's health regulator said on Wednesday it was reviewing French drugmaker Valneva's chikungunya vaccine after ...

Older adults are being warned against receiving the chikungunya vaccine before traveling. The Ixchiq vaccination, developed by Valneva to prevent the mosquito-borne chikungunya virus, was approved ...

Key Takeaways U.S. health agencies are investigating possible side effects of a chikungunya vaccineOlder adults, especially ...